Innovative light-activated antimicrobial treatment has potential to become first FDA-approved nasal decolonization treatment for prevention of surgical site infections Ondine’s light-activated antimicrobial therapy for nasal decolonization would apply to more than 35 million major surgical procedures in the USA annually. Surgical site infections (“SSIs”) account for 20% of all [...]

This Announcement uses a US$:£ exchange rate of 1 : 0.808210 as at 16:30 (GMT) on 2 January 2025. Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company developing light-activated antimicrobial treatments, is pleased to announce that hInsight-NX, LLC, a subsidiary of HCA Healthcare, Inc., a leading healthcare [...]

Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company, has enrolled and treated the first patient in the Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections (‘LANTERN’) Phase 3 clinical trial. The trial, involving approximately 5,000 patients in 14 hospitals, is evaluating Ondine’s non-antibiotic nasal photodisinfection technology, branded [...]

Ondine announced today the imminent start of the LANTERN Phase 3 clinical trial of its novel nasal photodisinfection technology, branded as Steriwave® outside the US. The U.S. Food and Drug Administration (FDA) has raised no objections to starting the study during its statutory 30-day review period of the Company's [...]

Updated November 15, 2025 to reflect further funds raised. Canadian life sciences company Ondine Biomedical announces that it is accelerating its final preparations for a Q4 2024 start to its key pivotal US Phase 3 trial following its recent successful raise of Cdn $19.2 million (c. £10.8 million). Alongside [...]

Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that it has made significant progress with the commercial roll-out of its novel nasal decolonization technology, Steriwave®, in both Canada and the UK. Steriwave is a simple 5-minute procedure that reduces healthcare-associated infections [...]

Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, confirms that King’s College Hospital (KCH) will be running a pilot of its Steriwave® light-activated antimicrobial technology. KCH, a globally recognized leader in healthcare innovation and one of London’s largest teaching hospitals, will be [...]

Ondine receives regulatory approval for Steriwave light-activated antimicrobial technology in the United Arab Emirates Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that it has received regulatory approval to market Steriwave® nasal decolonization to reduce healthcare-associated infections (HAIs) in patients undergoing [...]

Royal Columbian Hospital Foundation’s Advancing Innovation in Medicine (AIM) division supports Steriwave ICU use with clinical trials at Royal Columbian Hospital Treatment of patients in intensive care units (ICUs) would significantly expand Ondine’s market opportunity. Infection prevention is a top priority in ICUs as they face higher infection [...]

All references to C$ in this announcement are to Canadian Dollars. This Announcement uses a C$:£ exchange rate of 1 : 0.555041 as at 16:30 (GMT) on 23 September 2024. Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that it has agreed [...]